Axsome Therapeutics Inc (AXSM)

[georgejjl]

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced a presentation of data from its ACCORD Phase 3 clinical trial of AXS-05, a novel, oral NMDA receptor antagonist and sigma-1 receptor agonist, in patients with Alzheimer’s disease agitation (ADA), at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held in Boston from Oct. 24-27.

“Agitation associated with Alzheimer's dementia is a common and impactful behavioral symptom causing significant distress for patients and their care partners,” said George Grossberg, MD, study author, Professor and Director of the Division of Geriatric Psychiatry at the Saint Louis University School of Medicine. “Agitation is also a significant risk factor for early admission to long term care facilities. The outcome of the ACCORD trial with AXS-05 demonstrating positive efficacy results in agitation associated with Alzheimer's dementia, while being generally well-tolerated, is welcome news."

Results of the trial demonstrated rapid and sustained clinical response in patients with ADA during the open-label AXS-05 treatment phase. During the placebo-controlled randomized withdrawal phase, AXS-05 statistically significantly delayed the time to relapse of agitation symptoms as compared to placebo. AXS-05 was generally well-tolerated in the trial with no new safety signals identified.

“Agitation, which is seen in up to 70% of people with Alzheimer’s disease, is among the most complex, challenging and costly aspects of care and is associated with multiple negative outcomes such as increased caregiver burden, morbidity, mortality, earlier nursing home placement, and overall functional impairment,” said Cecilia Brain, MD, PhD, Vice President of Medical Affairs at Axsome. “The detailed efficacy and safety results of the ACCORD trial support the potential of AXS-05 in this area of significant unmet medical need.”

The poster will be available for viewing in the Poster Hall from 7:30 a.m. Eastern Time on Wednesday, Oct. 25 to 4:30 p.m. Eastern Time on Friday, Oct. 27. Poster presenters will be on hand for discussion from 7:30-8:30 a.m. Eastern Time as well as during the morning and afternoon coffee breaks each day during the CTAD conference. The poster will also be available through the CTAD digital platform.

https://finance.yahoo.com/news/axsome-therapeutics-presents-results-accord-110000892.html

Good luck and GOD bless,